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Abstract
Background: Infectious diseases emerge frequently in China, partly because of its large and highly mobile
population. Therefore, a rapid and cost-effective pathogen screening method with broad coverage is required for
prevention and control of infectious diseases. The availability of a large number of microbial genome sequences
generated by conventional Sanger sequencing and next generation sequencing has enabled the development of a
high-throughput high-density microarray platform for rapid large-scale screening of vertebrate pathogens.
Methods: An easy operating pathogen microarray (EOPM) was designed to detect almost all known pathogens
and related species based on their genomic sequences. For effective identification of pathogens from EOPM data, a
statistical enrichment algorithm has been proposed, and further implemented in a user-friendly web-based
interface.
Results: Using multiple probes designed to specifically detect a microbial genus or species, EOPM can correctly
identify known pathogens at the species or genus level in blinded testing. Despite a lower sensitivity than PCR,
EOPM is sufficiently sensitive to detect the predominant pathogens causing clinical symptoms. During application
in two recent clinical infectious disease outbreaks in China, EOPM successfully identified the responsible pathogens.
Conclusions: EOPM is an effective surveillance platform for infectious diseases, and can play an important role in
infectious disease control.
Background
The frequent invasion of microorganisms, including vi-
ruses, bacteria, fungi, parasites, and other eukaryotic and
prokaryotic organisms, has threatened and will continue
to threaten the life and health of humans and other
vertebrates. In recent years, mutant or new forms of
some existing pathogens have been identified as the
causative agents of a number of outbreaks that have
endangered public health in China [1]. Severe acute re-
spiratory syndrome (SARS), caused by a coronavirus,
spread throughout Guangdong Province in 2003, followed
by a worldwide epidemic. During the epidemic, 66% of the
SARS cases were reported in China, resulting in 349 human
deaths [2]. In 2007, an outbreak of hand, foot, and mouth
disease (HFMD) infected 1149 persons and caused the
death of three children in Linyi City, Shandong Province,
China [3]. The 2009 influenza A (H1N1) pandemic affected
more than 154,000 human patients, leading to 842 deaths
in China alone [4]. Because of its large and highly mobile
population, the emergence of infectious diseases in China is
relatively more frequent. Therefore, a system implemented
by the medical community and government for the moni-
toring of pathogens that could have a significantly negative
impact on public health is urgently required in China.
China has an established hospital-based surveillance
system for infectious diseases. All clinical and hospital
reports of both suspected and confirmed cases of notifi-
able infectious disease must be sent to local Centers for
Disease Control (CDC). The information is then sent to
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the China CDC headquarters in Beijing through the
National Infectious Diseases Monitoring Information
System Database, which was established in 2004. The
hierarchical administrative organization of the surveillance
system ensures a rapid and efficient upward flow of
epidemic information [5]. Based on this system, devel-
opment of effective diagnostic platforms can greatly
enhance the prevention and control of infectious diseases
in China. The predominant techniques for identification
of microbial pathogens depend on conventional clinical
microbiology monitoring approaches. Although well
established, these approaches usually require culture of
the pathogens, followed by susceptibility tests, which
are time-consuming and laborious. In addition, many
microbes are difficult to culture, and may be undetectable
by culture-based approaches.
Molecular approaches for microbial surveillance and
discovery have emerged as a very promising alternative
for early diagnosis of infectious diseases. Currently,
molecular approaches include traditional Sanger DNA
sequencing, polymerase chain reaction (PCR), oligonucleo-
tide microarrays, and next generation sequencing (NGS).
Among these four technologies, the former two can identify
a few known pathogens that must then be confirmed indi-
vidually, and thus cannot cover a wide range of pathogens.
The latter two methods cover a broad range of pathogens,
and are therefore suitable for identifying unknown or even
novel pathogens in infectious outbreaks. Although NGS
produces the most in-depth, unbiased information, and can
reveal completely novel organisms, it is time-consuming
and expensive, especially for the analysis of complex
samples [6]. DeRisi and colleagues developed the first
generation of microarray platform, called ViroChip, to
detect a wide range of viruses [7]. In 2003, the ViroChip
helped to characterize SARS as a novel Coronavirus [8].
Since then, ViroChip has also been used to detected a
human metapneumovirus [9], a novel influenza virus [10],
and a novel adenovirus [11]. More recently, GreeneChip
and MDA microarrays have been developed, which are
broader spectrum approaches that can detect several
thousand pathogenic viruses, bacteria, fungi, and protozoa
[12,13]. The aforementioned three platforms all used
long oligonucleotide probes and random amplification
of nucleic acids.
In this study, we report the construction of a high
throughput pathogen microarray platform, named Easy
Operating Pathogen Microarray (EOPM), for large-
scale pathogen surveillance and discovery in China.
The platform uses similar technical features to previ-
ous methods, but will be more useful for clinical appli-
cations because of its user-friendly analysis software.
The EOPM was designed based on the latest versions
of nucleic acid sequence resources for microbes. Clinical
application of the microarray system confirmed that it
can correctly identify the pathogens responsible for in-
fectious disease.
Methods
Collection of nucleic acid sequences of vertebrate
pathogens
Release 111 of the European Molecular Biology Laboratory
(EMBL, http://www.embl.org/) database (March 2012) was
used to establish our vertebrate viral sequence database.
The terms at the family level that describe the host as a
vertebrate animal were extracted from the “Virus Taxonomy
List 2012” (http://ictvonline.org/virusTaxonomy.asp?
version=2012), compiled by the International Committee
on Taxonomy of Viruses (ICTVdB). We only considered vi-
ruses under these taxonomy nodes. We also downloaded
the sequences of fungi and parasites from EMBL. 18S
rRNA sequences were extracted using the CDS tag. Finally,
we obtained bacterial 16S rRNA sequences from the Ribo-
somal Database Project (RDP 10.28, http://rdp.cme.msu.
edu). The final integrated dataset included 1,358,528
viral sequences representing complete and partial viral
genomes, 2,110,258 bacterial 16S rRNA sequences,
621,351 fungal 18S rRNA sequences, and 1,735,744
18S rRNA sequences from parasites. The EOPM Chip
distinguishes all 2,554 known vertebrate virus species
(involving 151 genera, 36 families), 124 bacterial genera
(involving 53 families), 38 fungal genera (involving 17 fam-
ilies), and 47 genera of parasites (involving 24 families).
Considering that bacterial 16S rRNA genes show a relatively
high level of homology, and that bacteria require the pres-
ence of active virulence genes for pathogenesis, 58 virulence
genes were selected, including rfbE, slt-1, ipaA, and katG,
and probes were designed against these gene sequences.
EOPM chip design and fabrication
The basic design of the viral probes included as many
different genomic target regions as possible for each
species of vertebrate virus in the EMBLdB. First, probes
were targeted to conserved regions in areas encoding
the structural proteins. The protein families database
(Pfam, http://pfam.sanger.ac.uk/) of multiple sequence
alignments was used to cluster the functionally related
sequences [14]. The regions tagged as 5′ UTR, 3′ UTR,
and LTR were also extracted and used as candidate se-
quences for the following probe design. Second, candidate
probes were screened according to the following criteria:
probes with a length of 60 nt, no repeats exceeding a length
of 8 nt, no hairpins with stem lengths exceeding 10 nt, GC
content between 30–70%, and Tm from 60–80°C. Third,
we used BLAST analysis to select the conserved viral
probes at the genus level from all of the candidate probes.
The extent of conservation was evaluated for each probe,
and all were found to detect the majority of species in each
genus. A target species was considered to be represented if
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a probe matched it with at least 75% sequence identity.
Probes conserved at the genus level were selected based
on a flexible threshold because the sequence conservation
between species belonging to different genera is quite vari-
able. Finally, we aligned the sequences of all the candidate
probes against the nt database, which was downloaded
from NCBI FTP in August 2012. Probes with high se-
quence similarity to non-target genomes were eliminated.
Both species-specific and genus-conserved probes were
included in the final probe set.
The identification of bacterial, fungal, and parasite
probes was similar, but only focused on the 16S and 18S
rRNA sequences. In addition, probes were also designed
to target 1160 host immune response genes as a potential
index to pathogenesis.
The 60-mer oligonucleotide probes were synthesized on
a 75 mm × 25 mm glass slide by applying an inkjet depos-
ition system (Agilent Technologies, Palo Alto, CA). A total
of eight sub-arrays with 60,000 distinct 60-mer probes in
one slide were customized. All hybridizations involved
a fluorescently-labeled synthetic oligonucleotide that
was complementary to a positive control probe, which was
replicated for more than 4,000 spots scattered in different
zones of each sub-array. This ensured that signals appeared
in every zone of each sub-array to facilitate data extraction
from hybridization figures.
Sample preparation and EOPM hybridization
Microbial nucleic acids were extracted from serum,
plasma, throat swabs, nasal lavage, feces, cerebrospinal
fluid, and other body fluid using a TIANamp Virus DNA/
RNA Kit (TIANGEN Biotech., Beijing, China). The carrier
RNA from the kit was applied to extract virus nucleic acid
with low molecular weight. The kit can be used to ex-
tract the nucleic acid from both RNA and DNA viruses
(like adenovirus), as well as bacteria, fungi, and parasites. A
previously described random PCR amplification strategy [7]
with minor modification was applied to amplify extracted
nucleic acids and label amplified products with fluorescent
dye. In brief, the first cDNA strand was reverse tran-
scribed with a random decamer heeled with a PCR primer
(5′-GTTTCCCAGTCACGATCNNNNNNNNN-3′). The
first strand cDNA was then synthesized to double-stranded
DNA using the same primer and Klenow DNA polymerase
(Takara, Dalian, China). Double stranded cDNA from both
patients and normal controls was PCR amplified using the
heel primer. Resultant PCR amplicons were then purified
and labeled with Cy3-dCTP or Cy5-dCTP for the normal
controls and patient samples, respectively, using Klenow
polymerase (Takara). Labeled DNA was mixed with 60 μl
of hybridization buffer and added to the 8 × 60,000 EOPM
arrays for hybridization overnight at 65°C in a hybridization
oven (Agilent). The EOPM arrays were then washed with
2× SSC, 0.005% Triton X-100 at room temperature for 1
min, followed by a second wash with 0.2× SSC at 37°C for
1 min. The arrays were then scanned using a dual-laser
scanner (Agilent) and the images were extracted and ana-
lyzed using Feature Extraction software (Agilent).
EOPM data analysis
The normal distribution of microbes in the human body
should be considered when using EOPM to identify
pathogens that are responsible for obvious clinical symp-
toms. We used two strategies to eliminate the background
of normal microflora. Firstly, at the experimental level,
we always compared the suspected clinical sample with
a normal sample of the same type, i.e. serum vs. serum or
feces vs. feces. Secondly, on a database level, we compared
clinical samples with the same type of samples from a data-
base that included more than 30 different samples from a
normal population, such as serum, feces, cerebrospinal
fluid, and throat swabs. The second aspect may avoid unex-
pected issues in the experimental normal control. Under
the above strategy, each clinical sample was first compared
with a normal control, and then with the normal sample
database, so that potential pathogens should be identified
based on their increased distribution compared to the
normal human samples.
To facilitate the application of EOPM in multiple sur-
veillance sites for infectious diseases, we designed software
with a user-friendly interface, which is supported by a stat-
istical analysis method based on a comprehensive microbial
sequence identification database.
In microbial diagnostic microarrays, only a few probes
are designed for each targeted microbe, and each probe
should be confirmed with specific positive and negative
samples. In the pan-microbial microarrays, many probes
are designed for one pathogen, and there is no way to
confirm each probe. However, the majority of the probes
targeting an expected pathogen are likely to be positive,
and not hybridize with other non-target microbes. We
applied a hypergeometric distribution to calculate a p-value
for each species as an assessment of statistical significance.
Whether a pathogen was significantly present was deter-
mined using a complex interpretation method. The formula








where C stands for the combination formula; N is the
whole number of microbial probes on an array; M is the
number of probes for a target microbe; n is the number of
probes for which the intensity is positive on an array; and
m is the number of probes whose intensity is positive for a
target microbe. The probes were ranked by the signal of
the Cy5 fluorescent dye that was used to label the patient
sample. In the user-interface of the EOPM software, the
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proportion of probes can be chosen by the user according
to the sample types. A small p-value indicates that there is
a very low likelihood that a mistake has occurred in the
multi-probe analysis, and correspondingly, that there is
a high probability of the existence of the target microbe.
Finally, the p-value is adjusted using Benjamini and
Hochberg's FDR correction [15].
Because the probes were designed to both the species
and genus levels, results will be given accordingly. In
EOPM analysis, when there were at least three positive
probes for a specific species of pathogen and an en-
richment p-value < 0.01, the given species could be
considered positive for further investigation, including
the clinical symptom coincidence analysis.
Sensitivity test for EPOM
Molecular detection methods, including pan-microbial
microarrays and unbiased high throughput sequencing,
traditionally rely on random amplification, and so have
lower sensitivity than specific PCR [16]. Clinical samples
usually contain host nucleic acid which may interfere
with the sensitivity of microarray analysis. To determine
the sensitivity of EPOM, we spiked viral RNA into human
RNA, mimicking the actual clinical samples. Enterovirus
71 (EV71), a single-stranded RNA virus, was cultured
with Vero cells. The RNA from the culture supernatant
medium was extracted and quantitatively determined
using a qRT-PCR standard curve. Then, 103–108 EV71
molecules were spiked into RNA extracted from 1012
human HeLa cells. The RNA was then randomly amplified
and hybridized with the EOPM microarray as described
above. In parallel, RT-PCR using a pair of specific primers
to amplify EV71 was performed to compare the sensitivity
of the two methods.
EOPM verification using known pathogens and clinical
sample tests
Known pathogens, including cell-cultured viral reference
strains, cultured bacteria, and fungi, were used to ver-
ify EOPM performance. Clinical samples were all from
patients with obvious infectious disease symptoms and
which obtained negative results with routine diagnostic
methods. Following detection by EOPM, the screened
pathogens that caused similar clinical symptoms to those
of the patients from which the clinical samples were
collected were PCR amplified with species- or genus-
specific primers. PCR-positive samples were then se-
quenced. This study obtained ethical approval from
Ethical Committee of Guangdong Women and Children’s
Hospital. Informed consent was not required because
clinical samples were screened for potential pathogens
in vitro. Original microarray data have been submitted




High throughput microarrays with long oligonucleotide
probes, such as the Virochip and GreeneChip systems,
have proved effective for pathogen screening [9,11,17,18].
The EOPM technique described here also uses long oligo-
nucleotide probes and random PCR amplification.
Several known viruses, bacteria, and fungi were used
to evaluate the accuracy of EOPM. Dengue virus was
used as a test subject to determine whether the EOPM
method could detect the virus from an infected C6/36 cell
culture (Tables 1, 2, and 3). As shown in Table 1, among
the 15 top ranked probes, eight targeted dengue virus
specifically, while a further four probes targeted related
flavivirueses such as Phnom Penh bat virus, Tembusu
virus, and deer tick virus. We also carried out enrichment
analysis of the positive probes at both the species and
genus level. Notably, only dengue virus or closely related
species showed significant enrichment (Table 2), and
only Flavivirus showed significant enrichment at the genus
level (adjusted p-value<0.0001) (Table 3). Both results were
consistent with the known cultured dengue virus.
By following a similar procedure, we successfully tested
EOPM on a panel of other known pathogens, including
an RNA virus, a DNA virus, bacteria, fungi, and parasites
(listed in Table 4).
In terms of detection sensitivity, EOPM could reliably
detect EV71 when >106 copies of EV71 RNA were mixed
into 1012 copies of HeLa cell RNA, while 103 copies of
spike virus RNA could be detected in 1012 copies of host
RNA by specific RT-PCR following agarose gel electrophor-
esis. Therefore, we inferred that when there was a high level
of background nucleic acid, the detection sensitivity of ran-
dom primer amplification was three orders of magnitude
lower than specific primer amplification.
Clinical case 1: identification of adenovirus responsible
for an outbreak of flu-like infections
Most adenovirus infections cause similar symptoms to
those induced by some respiratory viruses and myco-
plasmas, making it difficult to identify the pathogens by
traditional clinical diagnostic procedures. In February of
2012, an outbreak of disease caused by an unknown
pathogen occurred in Baoding City, Hebei Province.
Patients presented with obvious infectious symptoms,
such as high fever, coughing, throat congestion, lung tissue
necrosis, and bronchopneumonia. Initially, influenza
virus, SARS virus, and mycoplasma, known causes of
these clinical symptoms, were suspected, but PCR tests
were negative for all three pathogens. To rapidly identify
the unknown pathogen, EOPM chips were selected to
screen the possible pathogens responsible for these in-
fections. Nucleic acid was extracted from patient serum
samples to be used for EOPM analysis. Nucleic acid from
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normal serum was used as a control. One scanned
microarray image is shown in Figure 1, and the enrichment
results for the top-ranked pathogens at species and
genus level are listed in Tables 5 and 6 respectively.
Adenoviruses were found to be significantly enriched, as
were the top five species results (Tables 5 and 6). We
further verified adenovirus as the causative agent by
PCR targeted to a conserved region of Mastadenovirus
genomic sequence (see Additional file 1).
Clinical case 2: cardiovirus discovery in a
hand-foot-and-mouth juvenile patient
Hand-foot-and-mouth disease (HFMD) is a common viral
illness that predominantly affects infants and children
younger than 5 years old. HFMD epidemics usually occur
in China in late spring and early summer. The pathogens
responsible for HFMD are mainly coxsackie A16 virus
(CVA16) and enterovirus 71 (EV71), both of which belong
to the Enterovirus genus. The routine HFMD clinical diag-
nosis includes three qRT-PCR kits targeting the Enterovirus
genus, CVA16, and EV71 species respectively.
In May of 2010, many children were found to have
clinical symptoms of “hand-foot-and-mouth diseases” at
Guangdong Women and Children’s Hospital, located in
southern China. Although most patients were diagnosed
as having CVA16 or EV71 infections by the qRT-PCR
analysis, some were negative for Enterovirus. To identify
the pathogens responsible for Enterovirus-negative HFMD
children, samples from each of the patients were subjected
to EOPM analysis. About 1 mg of a feces sample was used
to extract RNA, using a TIANamp Virus DNA/RNA Kit,
and labeled with Cy5 following random amplification. In
Table 1 Top 15 probes identified in EOPM analysis of cell culture infected with dengue virus
Probe cy3 intensity cy5 intensity Ratio (cy5/cy3) Species Genus
Vm.27 145 65529 452 Dengue virus Flavivirus
Vm.20 218 65529 301 Dengue virus Flavivirus
bacts.2149 287 65529 228 Mycoplasma Mycoplasma
Vm.9835 232 52365 226 Sendai virus Respirovirus
Vm.21 332 65529 197 Dengue virus Flavivirus
Vm.23 334 65529 196 Dengue virus Flavivirus
Vs1.7636 352 65529 186 Phnom Penh bat virus Flavivirus
Vm.41 370 65529 177 Dengue virus Flavivirus
Vm.9292 453 65529 145 Tembusu virus Flavivirus
bacts.5220 286 37895 133 Staphylococcus Staphylococcus
Vs1.7675 543 65529 121 Deer tick virus Flavivirus
Vm.24 162 18867 116 Dengue virus Flavivirus
Vm.1 280 31761 113 Dengue virus Flavivirus
Vm.40 198 19474 99 Dengue virus Flavivirus
Vs1.7671 791 65529 83 Deer tick virus Flavivirus
The probes were ranked by ratio of cy5/cy3 intensity. Non-infected cell samples were labeled with cy3, and virus infected cell samples were labeled with cy5.
Table 2 Enrichment analysis of pathogens at the species
level in dengue virus-infected samples
Species m M N-M n Adjusted p-value
Dengue virus 14 41 55016 550 0.00E+00
Deer tick virus 5 10 55047 550 8.20E-06
Mycoplasma 4 55 55002 550 0.5073
A-2 plaque virus 2 8 55049 550 0.6017
Phytomyza 5 100 54957 550 0.6325
Orf virus 6 150 54907 550 0.6859
Brevibacterium 3 41 55016 550 0.9211
N: the total number of probes on the EOPM platform; M: the number of
probes designed for a target species; n: the number of positive probes
identified in a microarray; m: the number of positive probes for a species. The
top 1% of the total number of probes was considered to be positive probes.
Table 3 Enrichment analysis of pathogens at the genus
level in dengue virus-infected samples
Genus m M N-M n Adjusted p-value
Flavivirus 42 1697 53360 550 1E-05
Mycoplasma 4 57 55000 550 0.3075
Phytomyza 5 97 54960 550 0.3321
Mycoemilia 3 29 55028 550 0.3609
Aspergillus 3 40 55017 550 0.6627
Brevibacterium 3 41 55016 550 0.6869
Varicellovirus 10 429 54628 550 0.7028
Thogotovirus 4 83 54974 550 0.7336
Avipoxvirus 7 272 54785 550 0.893228
Orthopoxvirus 10 496 54561 550 0.933598
N and n are the same as for Table 2. M: the number of probes designed for a
target genus; m: the number of positive probes for a genus.
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parallel, RNA extracted from normal feces was labeled
with Cy3 and used as a control. The enrichment analysis
at the species level identified Theiler’s-like Cardiovirus as
the most probable pathogen responsible for the HFMD
infection in these patients (Table 7). Analysis of the en-
richment results at the genus level revealed Cardiovirus
as the number one match, showing significant enrich-
ment (Table 8). The genera Cardiovirus and Enterovirus
belong to the family Picornaviridae, a family of positive
single-stranded RNA viruses. A few intestinal viruses of
the Picornaviridae family, besides the enterviruse strains
coxsackie A virus and enterovirus 71, are also known to
potentially cause HFMD syndrome. Therefore, we hypoth-
esized that the Enterovirus-negative HFMD children were
actually infected with Cardiovirus, the sister genus of
Enterovirus. To confirm the presence of Cardiovirus in
patent feces, two specific nested RT-PCR primers pro-
posed in a previous report [19] were used to amplify the
RNA extracted from the Enterovirus-negative patients.
Samples were Cardiovirus-positive (see Additional file 2).
The PCR products were further verified by DNA se-
quencing, and 708 bp of the PCR amplicon shared 99%
nucleotide identity with human TMEV-like Cardiovirus
isolate UC2 5' UTR.
The microarray raw data of other symptom-causing
pathogens, such as streptococcus and mycoplasma, identi-
fied by EOPM in peripheral blood in infectious patients,
were also submitted to the GEO database.
Development of software with a user-friendly interface to
support the EOPM application
The primary purpose of developing the EOPM was to
facilitate the rapid identification of unknown pathogens
in regional surveillance centers in China when emergent
pathogen-causing incidents occur. When considering the
application of microarray technology, data analysis is a
significant obstacle to users without specialized knowledge
in bioinformatics analysis of microarray data and nucleic
Table 4 List of known pathogens from cultured samples
or confirmed pathogens from clinical samples that were
successfully detected by EOPM
Species Genus Description
Sindbis virus Alphavirus Positive stranded
RNA virus
Dengue virus Flavivirus Positive stranded
RNA virus
Human immunodeficiency virus Lentivirus Positive stranded
RNA virus
Entervirus 71 Enterovirus Positive stranded
RNA virus
Rubella virus Rubivirus Positive stranded
RNA virus
Human parainfluenza virus Respirovirus Negative stranded
RNA virus
Influenza B virus Orthomyxovirus Negative stranded
RNA virus
Rotavirus A Rotavirus Double stranded RNA
Mammalian orthoreovirus Orthoreovirus Double stranded RNA
Human adenovirus Mastadenovirus Double stranded
DNA virus
Group B streptococcus Streptococus Gram positive bacteria
Listeria monocytogenes Listeria Gram positive bacteria
Streptomyces cuspidosporus Streptomyces Gram positive
actinobacteria
cryptococcus magnus cryptococcus Fungi
Toxoplasma gondii Toxoplasma Parasite
Figure 1 Hybridization picture of EOPM in the adenovirus outbreak case. RNA/DNA from patients was labeled with red cy5 fluorescent dye,
and nucleic acid from normal control serum was labeled with green cy3 dye.
Table 5 Enrichment result at the species level for EOPM
analysis of the clinical outbreak case of respiratory
infection
Species m M N-M n Adjusted p-value
Unclassified adenovirus 14 150 54907 550 3.28E-08
Human adenovirus 11 80 54977 550 3.94E-08
Human adenovirus_type 35 5 12 55045 550 5.99E-06
Human adenovirus type 34 4 6 55051 550 1.20E-05
Human adenovirus type 7 4 22 55035 550 0.0049
Streptomyces 9 256 54801 550 0.0726
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acid sequences. Therefore, we implemented the statistical
enrichment analysis in a user-friendly interface (Figure 2).
The software can support a large-scale search of probe hits
against a comprehensive microbial sequence database. We
believe this software will greatly facilitate the installation of
the EOPM platform in different infectious surveillance sys-
tem laboratories in China. The software can be accessed at
http://www.genestone.com.cn:8080/microbial/index.jsp.
Discussion
Since the first application of a high-throughput, rapid,
and unbiased microarray for detecting viral pathogens
in 2002 [7], several pan-microbial microarray platforms
with different degrees of coverage of various pathogens
have been established. These microarray platforms use
long oligonucleotide probes (60–70-mer) and random
PCR amplification, and have successfully identified un-
expected pathogens in infectious disease outbreaks,
even discovering novel viruses with homology to known
species [8,11]. In this study, we constructed a high-density
EOPM array for screening all known viruses, bacteria,
fungi, and parasites that could become vertebrate path-
ogens. Based on the sequence data available for vertebrate
pathogens, we have designed 60,000 60-mer oligonucleotide
probes targeting 2,554 vertebrate virus species (involving
151 genera, 36 families), 124 bacterial genera (involving 53
families), 38 fungal genera (involving 17 families), and
47 parasite genera (involving 24 families). The 60-mer
oligonucleotide probes can cross-hybridize with similar but
non-identical sequences, allowing the detection of novel
pathogens that are related to known species. The EOPM
probes designed to detect bacteria, fungi, and parasites
were targeted to 16S rRNA or 18S rRNA sequences.
Whereas rRNA sequences are relatively conserved in
the same genus or family, EOPM can distinguish bac-
teria, fungi, and parasites at either the genus or family
level, which has already been successfully applied in a
clinical setting for confirmation and treatment. In the
sensitivity study of EOPM, we designed experiments to
compare the sensitivity of random amplification and
specific amplification, while not considering the effect
of other issues, such as clinical sample collection and
nucleic acid extraction, on the sensitivity of EOPM.
EOPM showed 103-fold lower sensitivity than specific
target PCR amplification, which was consistent with a
previous report [20]. The lower sensitivity was due to
the random PCR amplification adopted in the EOPM
sample preparation, which was not as efficient as specific
PCR for amplification of a particular species. Despite having
lower sensitivity than target-specific PCR, the EOPM
platform is sufficiently sensitive to identify the patho-
gens causing clinical symptoms in infectious outbreaks,
in which symptom-causing pathogens should be highly
enriched. The sensitivity can be further improved in
practice if acellular samples with minimal host nucleic
acid contamination, such as serum and throat swabs, are
used for pathogen screening. For example, Greninger and
colleagues had used ViroChip microarray to identify influ-
enza A/H1N1 in nasal swab samples showing a comparable
sensitivity with RT-PCR [10]. In the sample preparation
for the EOPM method, all RNA and DNA extracted from
samples are firstly reverse transcribed. RNA viruses are
converted into cDNA, and DNA viruses keep its DNA
status in the reverse transcription reaction, then the
DNA, including the reverse-transcribed cDNA and ori-
ginal DNA viruses, were transformed to double strand
DNA for the subsequent random amplification proced-
ure. Therefore, EOPM can detect both RNA viruses and
DNA viruses in the same standard protocol. For bac-
teria, fungi, and parasites, EOPM detects 16S rRNA or
18S rRNA copies encoded by rRNA genes located in the
genomic DNA. Because rRNA genes are highly transcribed,
detecting rRNA molecules instead of rRNA genes should
achieve higher sensitivity.
Table 6 Enrichment result at the genus level for EOPM
analysis of the clinical outbreak case of respiratory
infection
Genus m M N-M n Adjusted p-value
Mastadenovirus 54 455 54602 550 0.00E+00
Entomophthora 4 12 55045 550 0.0003
Streptomyces 9 258 54799 550 0.0728
Parvovirus 11 439 54618 550 0.2336
Erythrovirus 7 204 54853 550 0.2451
Streptococcus 5 118 54939 550 0.3556
Enterovirus 10 1964 53093 550 0.3957
Table 7 Enrichment result at the species level for EOPM
analysis of the Enterovirus-negative HFMD patients
Species m M N-M n Adjusted p-value
Theiler-like virus NGS910 5 10 55047 550 1.19E-06
Theiler's encephalomyelitis virus 5 30 55027 550 0.0006
Sleeping disease virus 2 11 55046 550 0.2259
Avian sarcoma virus 2 24 55033 550 0.6795
Congo hemorrhagic fever virus 2 54 55003 550 0.9891
Chagres virus 1 10 55047 550 0.9924
Table 8 Enrichment result at the genus level for EOPM
analysis of the Enterovirus-negative HFMD patients
Genus m M N-M N Adjusted p-value
Cardiovirus 15 110 54947 550 6.42E-12
Muromegalovirus 3 190 54867 550 0.9594
Coemansia 2 96 54961 550 0.9637
Arthrobacter 2 108 54949 550 0.9771
Nairovirus 2 146 54911 550 0.9923
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With the dual color strategy used by the EOPM method,
one normal sample without infectious symptoms was al-
ways analyzed in parallel. Despite this, the “normal” sample
may possess its own clinical characteristics. For example,
we have found Torque teno virus and human endogenous
retroviruses in some normal blood samples. These viruses
do not cause obvious clinical symptoms, and should not
interfere with the aim of EOPM analysis, which is to deter-
mine the possible pathogens causing the symptoms in the
test patients. EOPM data analysis consists of two steps.
First, we screened for significantly enriched microbes in the
target sample compared with the normal sample using the
dual color chip. Second, the predicted microbes identified
in the first step were compared with a database compiled
from the normal population mentioned above, to eliminate
the background microbes that also exist in normal samples
without infectious symptoms.
Pan-microbial screening microarrays differ from nu-
cleic acid-based microbial diagnostic technologies, such
as qPCR and low density microarrays. These diagnostic
technologies are merely aimed at identifying one or a
few types of microbes using target-specific probes that
should be confirmed with specific positive and non-specific
samples. Moreover, diagnostic low-density microarrays
usually use short oligonucleotides of about 20-nucleotides
as specific probes, similar to TaqMan probes in qPCR
technology [21,22]. The very limited number of short
probes/primers targeting a pathogen could fail to detect
sequences with mutations located in the regions targeted
by the probes/primers. However, over a dozen long
oligonucleotide probes were designed for each pathogen
in the EOPM method, allowing reliable identification of
a pathogen based on a statistical enrichment analysis of
the probe group, instead of one individual probe. Moreover,
EOPM can effectively narrow down the potential pathogens
and even identify novel pathogens in complex clinical infec-
tion situations.
In addition to the pathogen sequences, 1160 host im-
mune response genes were also included in the EOPM
database. During EOPM analysis of clinical samples, the
immune response genes show dramatic up- or down-
regulation in the target samples compared with the normal
reference (data not shown). So far we have not found any
reliable relationships between the immune response genes
Figure 2 User interface of the EOPM software. Users will generally only need to input raw microarray data for pathogen identification.
Huang et al. BMC Infectious Diseases 2013, 13:437 Page 8 of 10
http://www.biomedcentral.com/1471-2334/13/437
and the pathogen categories. The overall clinical infor-
mation for patients and normal controls should also be
comprehensively analyzed. Human immune related
genes in peripheral blood show dramatic differences
in expression even in a normal population, with differ-
ences correlated with sex, age, and sampling time,
amongst other factors [23,24].
Until now, the available genome-wide technologies to
detect unknown pathogens in infectious outbreaks pri-
marily consisted of microarrays and NGS. Although
NGS can provide the most in-depth, unbiased information,
and can reveal completely novel pathogens, it is time-
consuming when the sample contains hundreds of micro-
bial species that require comprehensive data processing.
Therefore, NGS cannot meet the short time requirement
for infectious disease control. However, the most compli-
cated step in EOPM technology is probe design, which can
be undertaken by a core bioinformatics team in the devel-
opment phase. Once probe design is complete, and the
whole microarray procedure is optimized as a standard
procedure, pathogen screening results can be interpreted in
less than 28 hours. Therefore, EOPM is more suitable for
applications requiring detection of unknown pathogens
during infectious outbreaks.
In addition, with the rapid increase in microbial
metagenomic sequence data produced by NGS, the probes
used for EOPM can easily be upgraded, and the EOPM ver-
sion can be updated due to the in situ synthesis technology
replacing the spotting technology in microarray fabrication.
Conclusions
In conclusion, EOPM is a very powerful pan-microbial
detection microarray platform, which can detect almost
all known pathogens and related species. In several clinical
test applications, we found that EOPM technology is
sensitive enough to detect the pathogens causing evident
clinical symptoms. EOPM is designed for easy operation,
with detection software containing a user-friendly inter-
face, facilitating its application in molecular laboratories.
Infectious disease epidemics emerge frequently in China,
and we believe that the use of EOPM in main pathogen
surveillance sites across the country could play an import-
ant role in infectious disease control in China.
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